Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumor heterogeneity

Christina S. Fjeldbo, Tord Hompland, Tiril Hillestad, Eva-Katrine Aarnes, Clara-Cecilie Günther, Gunnar B. Kristensen, Eirik Malinen, Heidi Lyng
doi: https://doi.org/10.1101/2020.05.28.20115386
Christina S. Fjeldbo
1Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tord Hompland
1Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
2Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiril Hillestad
2Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva-Katrine Aarnes
1Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara-Cecilie Günther
3Norwegian Computing Center, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar B. Kristensen
4Department of Gynaecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
5Institute for Cancer Genetics and Informatics, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eirik Malinen
6Department of Medical Physics, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
7Department of Physics, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi Lyng
1Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
7Department of Physics, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: heidi.lyng@rr-research.no
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Emerging biomarkers from medical imaging or molecular characterization of tumor biopsies open up for combining the two and exploiting their synergy in treatment planning. We compared pretreatment classification of locally advanced cervical cancer patients by two previously validated imaging- and gene-based hypoxia biomarkers, appraised the influence of intratumor heterogeneity, and investigated the benefit of combining them in prediction of chemoradiotherapy failure.

Experimental Design Hypoxic fraction, determined from dynamic contrast enhanced (DCE)-MR images, and an expression signature of 6 hypoxia-responsive genes were used as imaging- and gene-based biomarker, respectively, in 118 patients. Intratumor heterogeneity was assessed by variance analysis. The biomarkers were combined using a dimension reduction procedure.

Results The two biomarkers classified 75% of the patients with the same hypoxia status. Inconsistent classification in some cases was not related to imaging-defined intratumor heterogeneity in hypoxia, and hypoxia status of the slice covering the biopsy region was representative of the whole tumor. Hypoxia assessed by gene expression was independent on tumor cell fraction in the biopsies and showed minor heterogeneity across multiple samples in 9 tumors. Inconsistent classification was therefore rather caused by a difference in the hypoxia phenotype reflected by the biomarkers, providing a rational for combining them into a composite score. This score showed improved prediction of treatment failure (HR:7.3) compared to imaging (HR:3.8) and genes (HR:3.0) and significant prognostic impact in multivariate analysis with clinical variables.

Conclusion Combining our imaging- and gene-based biomarkers enables more precise and informative assessment of hypoxia-related chemoradiotherapy resistance in cervical cancer.

Competing Interest Statement

HL is registered as inventor of a patent application covering the clinical use of the hypoxia gene signature (WO2013/124738).

Funding Statement

The work was supported by grants from The Norwegian Cancer Society (Grant No 107438 and 182451), The South-Eastern Norway Regional Health Authority (Grant No 2015020), and The Norwegian Research Council (ELIXIR Norway).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Regional Committee for Medical and Health Research Ethics in southern Norway (S-01129). All patients gave written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data have been deposited in the gene expression omnibus (GEO) database (GSE146114), which will be released upon publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 29, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumor heterogeneity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumor heterogeneity
Christina S. Fjeldbo, Tord Hompland, Tiril Hillestad, Eva-Katrine Aarnes, Clara-Cecilie Günther, Gunnar B. Kristensen, Eirik Malinen, Heidi Lyng
medRxiv 2020.05.28.20115386; doi: https://doi.org/10.1101/2020.05.28.20115386
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumor heterogeneity
Christina S. Fjeldbo, Tord Hompland, Tiril Hillestad, Eva-Katrine Aarnes, Clara-Cecilie Günther, Gunnar B. Kristensen, Eirik Malinen, Heidi Lyng
medRxiv 2020.05.28.20115386; doi: https://doi.org/10.1101/2020.05.28.20115386

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1103)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (504)
  • Epidemiology (9787)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2323)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11660)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (339)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2192)
  • Public and Global Health (4676)
  • Radiology and Imaging (782)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (625)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)